MC2 Therapeutics to Present at Upcoming Conferences
26 Feb 2024
Phase 2Immunotherapy
MC2 Therapeutics to Present at Upcoming Conferences
MC2 Therapeutics to Present at Upcoming Conferences
Copenhagen, February 26th, 2024 – MC2 Therapeutics, a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation, announces today that its leadership will attend and present at the following industry conferences:
17th Annual European Life Sciences CEO Forum, Zürich February 28th-29th (presentation at 3:20pm CET, February 28th - Track C - Room Panorama C)
TD Cowen Annual Health Care Conference, Boston March 4th-6th (hosting 1:1 meetings with investors on March 4th at the event)
American Academy of Dermatology Annual Meeting, San Diego March 8th-12th
Kempen Life Science Conference, Amsterdam April 16th-17th (presentation on April 16th)
Bio€quity Europe, San Sebastian May 12th-14th (presentation time and location to be announced)
Any webcasts will be available on MC2’s website following the presentations. Please contact us if you would like to arrange a meeting.
About MC2 Therapeutics
MC2 Therapeutics is a commercial stage biotech company focused on developing novel treatment paradigms within immunology and inflammation. Its pioneering approach in immunology is anchored in a deep understanding of skin biology, clinical expertise and cross-silo thinking.
Its pipeline includes two first-in-class drug candidates both in Phase 2 clinical development, with novel modes of action and blockbuster potential in multiple indications (“I&I pipeline in a product”):
MC2-32: an oral HSP90 inhibitorHSP90 inhibitor with unique tissue specific targeting and a new MOA that modulates multiple pro-inflammatory pathways and relevant immune responses.
MC2-25: an iso-cyanate scavenger addressing carbamylation of proteins and amino acids in the skin by iso-cyanate, a dissociation product of urea.
For additional information on MC2 TherapeuticsMC2 Therapeutics, please visit www.mc2therapeutics.com.
Contacts:
Lonni Goltermann, +45 2018 1111, investor@mc2therapeutics.com
Media: ICR Consilium
Amber Fennell, +44 20 3709 5700, MC2@consilium-comms.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.